Cargando…

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR T cells) resulted in encouraging clinical trials in indolent B-cell malignancies. However, they also show the limitations of this fascinating technology: CAR T cells can lead to even life-threatening off-tumor,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cartellieri, M, Feldmann, A, Koristka, S, Arndt, C, Loff, S, Ehninger, A, von Bonin, M, Bejestani, E P, Ehninger, G, Bachmann, M P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022178/ https://www.ncbi.nlm.nih.gov/pubmed/27518241 http://dx.doi.org/10.1038/bcj.2016.61

Ejemplares similares

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
por: Aliperta, R, et al.
Publicado: (2015)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
por: Cartellieri, Marc, et al.
Publicado: (2013)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
por: Koristka, S, et al.
Publicado: (2014)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells
por: Cartellieri, Marc, et al.
Publicado: (2014)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
por: Aliperta, Roberta, et al.
Publicado: (2017)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy in acute myeloid leukemia
por: Koedam, Jan, et al.
Publicado: (2022)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)
por: Jureczek, Justyna, et al.
Publicado: (2020)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)
por: Mitwasi, Nicola, et al.
Publicado: (2022)

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging
por: Liu, Kaiyu, et al.
Publicado: (2015)

Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML
por: Sargent, J M, et al.
Publicado: (2001)

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in
por: Ehninger, Armin, et al.
Publicado: (2011)

Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy
por: Jin, Jing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8mrm99819biioc2gfb4n63n7df